A Girard1, C Ricordel2, E Poullot3, V Claeyssen4, O Decaux5, B Desrues2, P Delaval6, S Jouneau6. 1. Service de pneumologie, université de Rennes-1, CHU de Rennes, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex 9, France. Electronic address: anne.girard86@gmail.com. 2. Service de pneumologie, université de Rennes-1, CHU de Rennes, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex 9, France. 3. Service d'hématologie, université de Rennes-1, CHU de Rennes, 35033 Rennes, France. 4. Service des urgences, université de Rennes-1, CHU de Rennes, 35033 Rennes, France. 5. Service de médecine interne, université de Rennes-1, CHU de Rennes, 35033 Rennes, France. 6. Service de pneumologie, université de Rennes-1, CHU de Rennes, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex 9, France; IRSET UMR 1085, université de Rennes-1, 35043 Rennes, France.
Abstract
INTRODUCTION: Hydroxyurea is an antimetabolite drug used in the treatment of myeloproliferative disorders. Common adverse effects include haematological, gastrointestinal cutaneous manifestations, and fever. Hydroxyurea-induced pneumonitis is unusual. CASE REPORT: A female patient was treated with hydroxyurea for polycythemia vera. She was admitted 20 days after commencing treatment with a high fever, productive cough, clear sputum and nausea. A chest CT-scan showed diffuse ground-glass opacities. Microbiological investigations were negative. The symptoms disappeared a few days after discontinuation of the drug and rechallenge led to a relapse of symptoms. CONCLUSION: Our case and 15 earlier cases of hydroxyurea-induced pneumonitis are reviewed. Two patterns of this disease may exist: an acute febrile form occurring within 1 month of introduction of hydroxyurea and a subacute form without fever. Even if uncommon, one should be aware of this complication of hydroxyurea.
INTRODUCTION:Hydroxyurea is an antimetabolite drug used in the treatment of myeloproliferative disorders. Common adverse effects include haematological, gastrointestinal cutaneous manifestations, and fever. Hydroxyurea-induced pneumonitis is unusual. CASE REPORT: A female patient was treated with hydroxyurea for polycythemia vera. She was admitted 20 days after commencing treatment with a high fever, productive cough, clear sputum and nausea. A chest CT-scan showed diffuse ground-glass opacities. Microbiological investigations were negative. The symptoms disappeared a few days after discontinuation of the drug and rechallenge led to a relapse of symptoms. CONCLUSION: Our case and 15 earlier cases of hydroxyurea-induced pneumonitis are reviewed. Two patterns of this disease may exist: an acute febrile form occurring within 1 month of introduction of hydroxyurea and a subacute form without fever. Even if uncommon, one should be aware of this complication of hydroxyurea.
Authors: Andrew C Dietz; Yan Chen; Yutaka Yasui; Kirsten K Ness; James S Hagood; Eric J Chow; Marilyn Stovall; Joseph P Neglia; Kevin C Oeffinger; Ann C Mertens; Leslie L Robison; Gregory T Armstrong; Daniel A Mulrooney Journal: Cancer Date: 2016-08-09 Impact factor: 6.860
Authors: Elena Bargagli; Marco Palazzi; Francesco Perri; Elena Torricelli; Elisabetta Rosi; Alessandra Bindi; Massimo Pistolesi; Luca Voltolini Journal: In Vivo Date: 2017 Nov-Dec Impact factor: 2.155